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Abstract 
Epidemiological studies demonstrate that excessive drinking is associated with 
hypertension, cerebral bleeding and loss of cardiac contractility. Conversely, studies have 
shown that mortality rates for people who regularly drink ethanol in moderation are lower 
than in abstainers, primarily due to decreased fatal ischemic heart disease. Further, 
moderate ethanol consumers have lower rates of myocardial infarction compared with 
abstainers. These beneficial cardiac effects may be due to pleiotropic effects of ethanol on 
lipids, platelets, and fibrinolytic activity. During the past decade, studies conducted in 
several animal models have revealed that light to moderate regular ethanol consumption 
renders hearts more tolerant to myocardial ischemia-reperfusion injury; to a degree similar 
to cardiac ischemic preconditioning (brief episodes of ischemia dramatically limit infarct size 
following prolonged ischemia). Recent clinical evidence suggests that light to moderate 
ethanol consumption in the year prior to myocardial infarction is associated with reduced 
mortality following myocardial infarction. These findings suggest that light to moderate 
ethanol consumption not only prevents myocardial infarction but also improves survival after 
myocardial infarction. Proposed mechanisms of cardioprotection by regular ethanol 
consumption include activation of adenosine A1 receptors, α1-adrenoceptors, protein kinase 
C-δ and ε, adenosine triphosphate-dependent potassium (KATP) channels, nitric oxide 
synthase and reduced leukocyte-endothelial cell adhesive interactions. In this review, we 
focus on the recent progress in elucidating the endogenous myocyte signaling mediating 
cardioprotection by light to moderate ethanol consumption. 
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INTRODUCTION 
The link between ethanol and cardiovascular disease is important because diseases 
affecting the circulatory system are a leading cause of mortality in many developing 
countries. Numerous studies have demonstrated that excessive drinking is associated with 
cardiovascular disorders, including cardiomyopathy, hypertension, arrhythmia, coronary 
heart disease, cerebral bleeding and other life-threatening medical complications [1-3]. 
Especially, ischemic heart disease is most important all over the world. Since ancient times, 
however, it has long been recognized that ethanol in moderation is healthy; ethanol abuse 
detrimental. In the past century, epidemiological studies have shown that mortality rates for 
people who regularly drink ethanol in moderation are lower than in abstainers [1,2,4,5]. This 
is primarily due to decreased incidence of fatal ischemic heart disease [6,7]. The beneficial 
cardiac effects of moderate ethanol consumption may be due to the pleiotropic effects of 
ethanol on lipids [8], platelets, and fibrinolytic activity [9,10]. Even very low consumption of 
ethanol (one or two drinks per week) has been shown to be cardioprotective [11].  
Recent clinical studies demonstrated that light to moderate ethanol consumption 
may provide further cardioprotection, attenuating ischemia-reperfusion injury and improving  
outcome after acute myocardial infarction [12-16]. Moderate ethanol consumers improved 
survival after myocardial infarction compared with abstainers [13]. During the past decade, 
studies conducted in several animal models have revealed that light to moderate regular 
ethanol consumption renders hearts more tolerant to myocardial ischemia-reperfusion injury 
to a degree similar to cardiac ischemic preconditioning [17,18], in which brief episodes of 
ischemia and reperfusion dramatically limit infarct size following prolonged ischemia [19]. 
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We have termed this protective effect of ethanol against ischemia-reperfusion injury 
“ethanol preconditioning” [17]. 
Recognizing the deleterious effects of ethanol abuse on the heart and other organ 
systems, in this review, we discuss two potential beneficial effects of light to moderate 
ethanol consumption on the heart; prevention of coronary heart disease and reduction of 
ischemia-reperfusion injury. We review pleiotropic effects of ethanol which may contribute to 
decreased development of ischemic heart disease. We then discuss the endogenous 
myocyte signaling likely mediating ethanol cardioprotection against ischemia-reperfusion 
injury.  
 
Pleiotropic Effects of Ethanol: prevention of ischemic heart 
disease 
Clinical and epidemiologic studies show that moderate drinkers have less cardiovascular 
disease when compared with nondrinkers or heavy drinkers [1-3,20,21]. This is primarily 
due to a decreased incidence of coronary heart disease which results in a U-shaped or J-
shaped curve between ethanol consumption and mortality. Plausible mechanisms for this 
cardioprotection, as well as adverse effects of ethanol abuse, are shown in Figure 1. These 
mechanisms include increases in high density lipoprotein cholesterol (HDL-C), decreases in 
low density lipoprotein cholesterol (LDL-C) [22], decreased platelet aggregation, increased 
fibrinolytic activity, suppression of inflammatory cytokines and increased insulin sensitivity 
through increased levels of plasma adiponectin [23]. Ethanol consumption increases 
apolipoprotein A-I and A-II which are the main protein components of HDL-C [24]. Multiple 
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epidemiological studies have shown an inverse relationship between serum HDL-C 
(especially HDL3) level and morbidity due to ischemic heart disease [8,20,24-26]. Rimm at 
al., calculated that consumption of 30 g ethanol per day, regardless of beverage type,  
reduces ischemic heart disease events 16.8 % by increasing HDL-C [20]. Reports suggest 
that at least half of the beneficial effect of ethanol on atherosclerosis is attributed to 
increased HDL [27,28].  
 
Rao et al. demonstrated that light, but not heavy, ethanol consumption upregulates 
paraoxonase 1 expression [32]. Increased serum paraoxonase has been shown to limit 
LDL-C peroxidation and play a major role in the protective effect of HDL against coronary 
artery disease [33,34]. Ethanol induces qualitative changes on HDL-C which results in 
phospholipids enrichment. This is thought to reduce the inflammatory response of 
atherogenesis [35]. Anti-inflammatory effects by moderate ethanol consumption are well 
established. Imhof et al., studied a random cross-sectional sample of over 8000 men and 
women in three European countries to investigate the effect of ethanol consumption on 
inflammatory markers including white blood cell counts, fibrinogen and C-reactive protein 
(CRP). Moderate ethanol consumers was associated with lower levels of these markers 
[36].  
 
Moderate ethanol consumption may have beneficial effects on the vascular system, 
reducing CRP and adhesion molecules, including intercellular adhesion molecule (ICAM), 
vascular cell adhesion molecule (VCAM) and E-secletin [37,38]. Pai et al., studied over 
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1400 healthy men and women from a large prospective study. They found significant trends 
between increasing ethanol intake and soluble tumor necrosis factor-α (TNF-α) receptor 1 
and 2 . Compared with abstainers, men who consumed on average 1-2 drinks/day had 26% 
lower CRP and 36% lower interleukin-6, a proinflammatory cytokine. A similar association 
was observed in women who consumed half drink per day [39].   
Other proposed mechanisms for the protective effect of moderate ethanol 
consumption against ischemic heart disease events include beneficial effects on 
hemostasis [40], endothelial function and insulin resistance [41]. Moderate ethanol 
consumption has been shown to affect several hemostatic factors, including fibrinogen 
concentration, platelet aggregability, tissue plasminogen activator (t-PA) and plasminogen 
activator inhibitor [20,42-44]. Moderate ethanol consumption decreases platelet 
aggregation, increases fibrinolytic activity and reduces fibrinogen levels, as well as levels of 
the Von Willebrand factor, important in platelet adhesion and aggregation [45]. Endothelial 
cells also have been reported to play an important role in increased fibrinolytic activity 
induced by ethanol consumption [46]. Booyse et al., demonstrated that fibrinolytic protein 
such as t-PA expression is modulated by ethanol and wine polyphenols. Clot lytic rates 
significantly increased in mice treated with either ethanol, catechins and quercetin [30]. 
Nitric oxide (NO) produced from endothelial cell inhibits smooth muscle cell proliferation and 
platelet aggregation [47].  
Furuya et al. demonstrated that there is an inverted U-shaped relationship between 
ethanol intake and insulin sensitivity in an experimental model [49]. Bell et al., assessed the 
relationships between ethanol consumption and insulin sensitivity and coronary risk factors 
in a cross-sectional analysis of 1,196 subjects. They found that moderate ethanol 
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consumption was associated with improved insulin sensitivity and modifiable cardiac risk 
factors such as lipids and blood pressure [41].  
When considering the relationship between ethanol consumption and coronary heart 
disease, the role of confounding variables such as diet, physical activity and genetics 
cannot be ignored. Light to moderate ethanol consumption is associated with a lower 
prevalence of metabolic syndrome, with beneficial effects on lipids, waist circumference and 
fasting insulin [50]. Studies suggest that wine consumption is associated with a diet high in 
fruits, vegetables and fish and low in saturated fat (Mediterranean diet) [51,52] [53]. It has 
been demonstrated that the mortality of fatal ischemic disease is lower among the 
physically active who consume moderate ethanol [54].  
Genetic differences may also contribute to the variability in metabolic capacity of 
ethanol among individuals. This may in turn influence the magnitude of cardioprotection 
afforded by moderate ethanol consumption. Ethanol is metabolized by alcohol 
dehydrogenase (ADH) and the mitochondrial form of aldehyde dehydrogenase (ADH2) 
[55,56] The polymorphism of encoded genes for these enzymes changes their activity and 
the frequencies of these variants highly depend on the ethnicity. 
Finally, non-alcoholic components such as wine polyphenols and dietary 
isohumulones (the bitter components of beer) have been implicated in the beneficial effects 
of alcohol beverage on atherosclerosis [30,31]. However, it appears that their contribution to 
cardioprotection is minor comparedto the effects of ethanol. 
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Ethanol Preconditioning: attenuating cardiac ischemia-reperfusion 
injury 
We discovered that regular ethanol consumption renders hearts more tolerant to 
ischemia-reperfusion injury mimicking cardiac ischemic preconditioning. This protection 
against ischemia-reperfusion injury is mediated through adenosine A1 receptor activation 
[17]. In these early studies, guinea pigs were treated with 2.5-20% ethanol in their drinking 
water for 3-12 weeks. This corresponds to a range equivalent to mild to heavy ethanol 
consumption. Isolated hearts were perfused and subjected to 45 min of no-flow ischemia 
and 48 min reperfusion. The effect of varying concentrations of ethanol and duration of 
exposure is shown in Table 1. Treatment for 3 weeks with 10% ethanol in their drinking 
water induced cardioprotection. As little as 2.5% ethanol in the drinking water for 3 weeks 
protects only against a rise in left ventricular end-diastolic pressure (LVEDP) during 
reperfusion. However, by 6 weeks of treatment, full protection as indicated by improved left 
ventricular developed pressure (LVDP) recovery, decrease in LVEDP and creatine kinase 
release was seen regardless of dose of ethanol. The magnitude of this protection is similar 
to that of ischemic preconditioning elicited by 2 min of global ischemia and 5 min of 
reperfusion immediately before sustained ischemia in the absence of ethanol (Table 1). 
These salutary effects of ethanol consumption were abolished by the selective adenosine 
A1 receptor inhibitor, 8-cyclopentyl-1,3,dipropylxanthine (DPCPX), but not the A2 receptor 
inhibitor, 3,7-dimethyl-1-propargylxanthine (DNPX). This suggests that the adenosine A1 
receptor, but not A2 receptor, plays a crucial role in cardioprotection afforded by chronic 
ethanol consumption. In another study, we reported that the mechanism of a 
cardioprotection by regular ethanol consumption can vary by species. In rats, ethanol 
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preconditioning was mediated by α1-adrenergic signaling, not adenosine A1 receptor 
signaling[57]. We also demonstrated that chronic ethanol exposure induces sustained 
translocation of ε-protein kinase C (PKC) in myocytes from the cytosolic to particulate 
fractions, but not α-PKC and δ-PKC. Isolated myocytes from hearts exposed to ethanol  
showed immunolocalization of ε-PKC antibody fluorescence from the perinuclear and 
cytosolic regions to the cross-striations (possibly myofilaments), suggesting that ε-PKC had 
translocated to activation sites, binding to anchoring molecules (receptors for activated C 
kinase or RACKs). These data correlated with the data obtained by Western blot analysis 
[58]. Translocation of PKC has been to play a crucial role in triggering the signal 
transduction responsible for ischemic preconditioning [59]. Data from most other 
laboratories corroborate our data (Table 2). Guiraud et al. demonstrated that infarct size of 
the hearts from rat treated with 7% ethanol in their drinking water for 7 weeks was smaller 
than control after 30 min ischemia and 120 min reperfusion [60]. The combination of regular 
ethanol consumption and ischemia preconditioning further reduced infarct size. However, 
translocation of ε-PKC was not observed in rat myocytes. Pagel et al. employed the method 
of chronic, intermittent ethanol feeding to more fully mimic the clinical setting. Dogs were 
fed with ethanol (1.5g/day) mixed with dry food twice per day for 12 weeks. Infarct size of 
ethanol treated animals was significantly reduced compared with control [61]. Most, but not 
all, studies show that regular ethanol consumption protects myocardium against ischemia-
reperfusion injury. Dow et al. failed to demonstrate reductions in myocardial infarct size in 
rats treated with ethanol (15% or 36% in their drinking water) for 16 weeks [62]. Gibson et 
al. also reported that moderate and heavy amounts of alcohol (defined as 20% and 35% of 
total caloric intake) do not improve, and even worsen functionary recover (increased 
diastolic stiffness) after 21.5 min of ischemia followed by 30 min reperfusion in isolated rat 
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hearts [63]. The discrepancy among these studies remains unclear, but might be due to 
differences in experimental models (Table 2).  
 
Potential Mechanisms of Ethanol Preconditioning  
Numerous studies have been conducted to elucidate the mechanisms of 
preconditioning induced by regular ethanol consumption against ischemia-reperfusion injury 
in the past decade. The signal transduction by which regular ethanol consumption exerts a 
cardioprotective effect against ischemia-reperfusion injury is similar to that of ischemic 
preconditioning (Figure 2).  Adenosine mediates many of the acute and long-term effects of 
ethanol on cellular and organ functions [64,65]. Ethanol has been shown to increase 
extracellular adenosine by inhibiting adenosine uptake, which results in activation of 
adenosine receptors [66]. Experiments in pigs [67], rabbits [68], dogs [69,70], and studies 
with human tissue [71] indicate that adenosine A1 receptors mediate ischemic 
preconditioning. Involvement of adenosine A1 receptor activation in cardioprotection by 
regular ethanol consumption has been demonstrated in guinea pigs [17] and dogs [61], but 
not in rats [57].  
Chronic ethanol exposure in cells with adenosine A1 receptors causes 
hypersensitization of cAMP production [72], in contrast to cells expressing adenosine A2 
receptors where ethanol causes heterologous desensitization of cAMP signal transduction 
[73,74]. In rats, α1-adrenergic receptors have been implicated in cardioprotection by regular 
ethanol consumption [57]. Stimulation of these G-protein coupled receptors by chronic 
ethanol exposure initiates production of the second messenger diacylglycerol, and results in 
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activation of phospholipase C [75] and PKC [58]. PKC signaling is crucial for triggering 
ethanol preconditioning [76]. Inagaki and Mochly-Rosen demonstrated that activation of δ-
PKC induced by acute ethanol exposure mediated ε-PKC activation in ethanol-induced 
cardioprotection from ischemia [77]. Sustained translocation of ε-PKC from the cytosol to 
the myocyte membrane [58] or mitochondria [78] has been shown to play a role in ethanol  
preconditioning. ε-PKC primes both sarcolemmal [79] and mitochondrial [80] adenosine 
triphosphate-sensitive potassium channels (sarcKATP and mitoKATP) to open in ischemic 
preconditioning. Zhu et al. first demonstrated that mitoKATP channels are required for 
cardioprotection by chronic ethanol consumption in isolated rat hearts treated with 18% 
ethanol for 10 months [81]. Pagel et al. demonstrated that both sarcKATP and mitoKATP play 
a role in reducing myocardial infarct size by chronic, intermittent ingestion of small amount 
of ethanol in vivo dog hearts [82].  
NO is an important mediator in cardioprotection, activating mitoKATP [83]. Opening of 
mitoKATP increases levels of reactive oxygen species (ROS) in cardiomyocytes [84]. ROS 
activates a second pool of ε-PKC 1, designated ε-PKC 2, which inhibits the mitochondrial 
permeability transition. MitoKATP-generated ROS also activates ε-PKC 1 and induces 
phosphorylation-dependent mitoKATP opening. Thus mitoKATP-dependent mitoKATP opening 
constitutes a positive feedback loop capable of maintaining the channel open after the 
stimulus is no longer present. This feedback pathway may be responsible for the lasting 
protective effect of preconditioning, known as the memory effect [85]. 
Ethanol has been shown to increase antioxidant enzymes such as superoxide 
dismutase and catalase in myocytes [86]. A recent in vivo mouse study revealed that 
activation of ALDH2 by acute ethanol exposure is involved in the detoxification of toxic 
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aldehyde such as 4-HNE which mediates oxidative damage through activated ε-PKC 
translocated to mitochondria [78].  
NO increases ventricular function and serves as a signaling molecule at low 
concentrations [87,88], but triggers inflammation and suppresses contractile function at high 
concentrations [89]. Endothelial nitric oxide synthase (eNOS) is important for regulating 
basal vascular tone and blood pressure [90,91]. Cardiac myocytes also express eNOS [92] 
which plays a role in regulating myocardial contractile function and oxygen consumption 
[93] [94]. Knockout mice lacking eNOS suffer larger infarcts than wild type after ischemia 
[95]. eNOS overexpression in mice attenuates myocardial reperfusion injury [96]. Ethanol 
has been shown to increase NO production through modulation of eNOS expression [97]. 
Abou-Agag et al. reported that moderate ethanol consumption for 8 weeks (defined as 9% 
of total caloric intake) enhanced maximum vascular relaxation and increased plasma NO 
production concomitant with increase in eNOS protein in the vascular endothelium. In 
contrast, heavy ethanol consumption (defined as ~36% of total caloric intake) reduced 
maximum vascular relaxation [98]. We have recently demonstrated that ethanol 
preconditioning can be enhanced by administration of the volatile anesthetics, sevoflurane 
before ischemia through upregulation of eNOS by ethanol [99].  
We have recently examined how long ethanol’s cardioprotection persists after 
abstention and whether inducible NOS (iNOS) and/or eNOS play a role in this continued 
cardioprotection. Guinea pigs received 5% ethanol in their drinking water for 8 weeks. 
Isolated hearts were subjected to 30 min ischemia and 120 min reperfusion at 0, 4, 7 and 
14 days after abstention. Contractile recovery after ischemia-reperfusion was significantly 
improved at 0, 4 and 7, but not 14 days of abstention, compared to controls. Western blot 
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analysis and immunohistochemistry demonstrated upregulation of eNOS expression up to 7 
days, but not 14 days abstention. Expression of iNOS declined at 0 day. These data 
suggest that chronic cardioprotection against ischemia-reperfusion injury by regular ethanol 
consumption persists for at least 7 days after abstention. Increased eNOS activity plays a 
role in this persistent cardioprotection [100].  
Decreased expression of iNOS in ethanol treated hearts might be due to attenuation 
of inflammation. Growing evidence suggests that anti-inflammatory effects of moderate 
ethanol consumption not only reduce the incidence of coronary artery disease [101] but also 
attenuate inflammation after ischemia-reperfusion [102]. Previous experiments suggest that 
inflammation plays a role in ischemia-reperfusion injury [103]. NO derived from iNOS 
mediates cardiac dysfunction by inducing production of pro-inflammatory cytokines [104]. 
Cytokines such as IL-1, IL-6, and TNF-α are upregulated rapidly in response to myocardial 
ischemia [105]. Yamaguchi et al. found that the late phase of ethanol cardiac 
preconditioning correlated with reduced leukocyte-endothelial cell adhesive interactions, 
suggesting an anti-inflammatory effect [106]. This effect appears dependent on PKC [107]. 
eNOS was shown to be essential for the anti-inflammatory effects of the late phase of 
ethanol preconditioning [108].  
Recently, prevention of mitochondrial permeability transition pore (mPTP) opening 
by inhibition of glycogen synthase kinase 3β (GSK-3β) has been implicated in ischemic 
preconditioning [109]. Irreversible mPTP opening abolishes the mitochondrial membrane 
potential, disabling the mitochondria ATP production. GSK-3β is a substrate of multiple pro-
survival protein kinases, including Akt, ε-PKC, extracellular signal-regulated kinase 1/2 
(ERK) and protein kinase G. Inhibition through phosphorylation of GSK-3β by PI3/Akt 
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signaling is a key event for prevention of mPTP opening, increasing cell survival [110]. 
Zhong et al. reported that mice fed 18% ethanol in their drinking water for 12 weeks 
demonstrated sustained translocation of ε-PKC and increased expression of Akt [111]. 
Recently, Zhou et al. demonstrated that 10-500 µM (light) but not 1 mM (heavy) ethanol 
prevents mPTP opening by inhibiting GSK-3β in cardiac H9c2 cells [112].  GSK-3β has also 
been shown to play a role in apoptosis [113]. Active GSK-3β facilitates apoptosis induced 
through mitochondrial pathway, whereas it suppresses pro-apoptotic signaling from death 
receptors such as Fas, TNF-R1 and DR4,5 [113-115]. It remains unclear whether chronic 
alcohol consumption affects mitochondrial apoptotic protein, such as Bax, Bad and Bcl2 by 
modulating GSK-3β. Further studies are needed. As GSK-3β plays an important role in 
cardiomyocyte death, manipulation of this protein kinase by ethanol may help in developing 
strategy for cardioprotection. The role of other protein kinases such as protein tyrosine 
kinase and mitogen-activated protein kinase (MAPK) in cardioprotection by regular ethanol 
consumption has not been established. Both kinases have been implicated in ischemic 
preconditioning [116-118]. A study demonstrated that the infarct size limiting effect of acute 
ethanol exposure was abolished by genistein (non-selective protein tyrosine kinase) in 
isolated rabbit hearts [119]. MAPK such as p38 MAPK, ERK and c-Jun NH2-terminal (JNK) 
have been also implicated in ischemic preconditioning [120]. Sanada et al. reported that 
transient p38 MAPK activation during preconditioning is a trigger for IPC [118]. Involvement 
of ERK and JNK in cardioprotection by ethanol remains unclear. One study demonstrated 
that acute moderate ethanol exposure (4 or 8 mM), but not heavy exposure, to vascular 
smooth muscle stimulated ERK activity which was blocked by PKC inhibitor [121]. In 
contrast, Churchill et al. reported that intraperitoneal injection of ethanol (0.5g/kg) in mice 60 
min prior to ischemia-reperfusion reduced phosphorylation of ERK and JNK compared with 
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control hearts [78]. Further study will be needed to elucidate involvement of ERK and JNK 
in cardioprotection by regular ethanol consumption. 
 
Cardioprotection by Chronic Ethanol Consumption: dose, duration 
and washout 
A cardioprotection by regular ethanol consumption is dependent on the time and 
duration of ethanol exposure. The definition of one ethanol drink varies remarkably by 
publication and countries. The terms such as light, moderate and heavy drinking are vague. 
For example, one drink is 0.5 fl oz or 12 g of ethanol in USA, 8 g in England and 20-24g in 
Japan. According to Dietary Guidelines for Americans, moderate drinking is no more than 1 
drink (12 g of ethanol) per day for women and no more than 2 drinks (24 g of ethanol) per 
day for men [122]. In experimental studies, the concentration of ethanol varies significantly. 
There are differences in dose and duration of ethanol consumption, mode of administration, 
units used to express the amount of ethanol (mg/dl, mM etc.). Serum levels of ethanol 
fluctuate depending on the time of blood sampling as animals do not drink constantly 
through the day. Further, elimination rates of ethanol are different among species. For 
example, guinea pigs eliminate ethanol 50 to 60 % faster (2.59 micromol/g liver/min) [123] 
than humans (1.63-1.76 micromol/g liver/min) [124]. We fed guinea pigs a nutritionally 
supplemented liquid diet containing 15% ethanol-derived calories for 8 weeks [58]. This 
approximates the upper limits of moderate ethanol consumption in human (45 g of 
ethanol/day, at 7 kcal/g ethanol, results in ~15% ethanol-derived calories in a 2000 kcal 
diet) [125]. In this study, serum ethanol levels at 9-11am were 10±2 mg/dl (about 2.2 mM). 
The duration of treatment is also important. In our early studies of ethanol preconditioning, 
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the duration required for cardioprotection was at least for 3 weeks with 10% ethanol in the 
drinking water of guinea pig. Treatment for 3 weeks with 2.5% or 5% ethanol did not induce 
full protection [17]. Rat hearts treated with ethanol dosed at 9%(v/v) for 7 weeks [60] or 
18% (v/v) for 10 months [81] both showed a cardioprotection after ischemia-reperfusion, 
with average serum ethanol levels of 1.7±0.1 mg/dl (about 0.4 mM) or 15.4±0.6 mg/dl 
(about 3 mM), respectively. Pagel et al. fed dogs with ethanol (1.5g/day) mixed with dry 
food twice per day for 12 weeks. Average serum ethanol concentration was 11 mM [61]. 
Chen et al. used 10 mM ethanol to induce cardioprotection by acute ethanol exposure in 
isolated perfused rat hearts before and throughout ischemia [126]. However, the presence 
of ethanol during ischemia seems to have antiprotective effects in rabbit hearts. Krenz et al. 
demonstrated that ethanol levels of between 6 and 12 mM during ischemia abolished the 
protective effect of acute ethanol exposure in in vivo rabbit hearts [127]. They also found 
that ethanol at concentrations of 5-50 mM reduced infarct size if washed out before 
ischemia. They determined that a threshold ethanol level for cardioprotection in rabbit was 
approximately 3 mM. In previous studies from our laboratory, whether ethanol was 
withdrawn 12-16 h before ischemia (wash out) or ethanol was not withdrawn from the 
drinking water before sacrifice (serum ethanol levels at the time of sacrifice were 2.7±0.5 
mM in guinea pigs receiving 2.5% ethanol), cardioprotection from ischemia-reperfusion 
injury was observed [17,99]. 
Thus, the serum ethanol levels can vary remarkably depending on dosing, time of 
blood sampling, and species.  
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Clinical Perspective 
Data presented in this review would suggest that ethanol can be used as a potential 
cardioprotective therapeutic agent. However, the negative effects of excessive drinking 
must be taken into account. Heavy drinking is one of the leading preventable causes of 
death worldwide [128]. A recent study has shown that one in every 25 deaths worldwide 
and 5% of global disability-adjusted life-years are attributable to ethanol consumption [129]. 
Heavy drinkers have a much higher rate of morbidity and mortality that overcomes any 
potential benefit against ischemic heart disease. Yet, epidemiological evidence suggests 
that moderate drinking reduces the risk of ischemic heart disease. Further, animal data 
suggest that regular ethanol consumption protects against ischemia-reperfusion injury; a 
possible mechanism accounting for increased survival after myocardial infarction in 
moderate drinkers versus abstainers. And as stated above, we found that the infarct size 
limiting effect by regular ethanol consumption persists for at least 7 days after abstention. 
Nevertheless, it would be inappropriate to recommend drinking to patients to protect their 
heart. While ethanol itself cannot be recommended as a therapeutic agent, understanding 
the mechanisms underlying its cardioprotective effects could lead to safer therapies.  
 It is important to note that recent studies demonstrate acute (as opposed to chronic) 
ethanol exposure fails to exert a cardioprotective effect during ischemia-reperfusion [127]. A 
recent randomized, prospective study in human found that administration of a moderate 
dose of ethanol abolished ischemic preconditioning and was associated with worsening 
subsequent ischemia [130].  
 Elucidating the mechanism underlying ethanol cardioprotection may help in the 
development of cardioprotective therapies in the perioperative setting. We recently found 
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that the infarct size limiting effect by regular ethanol consumption is enhanced by 
sevoflurane [99]. Because anesthetics can be administrated with relatively low toxicity, 
elucidating the interaction between ethanol and volatile anesthetic-induced preconditioning 
and the underlying mechanisms may be beneficial for reducing perioperative myocardial 
ischemia-reperfusion injury. Growing evidence that long-term ethanol consumption mimics 
ischemic preconditioning opens a new avenue for developing novel therapies to improve 
outcomes in patient at risk for myocardial infarction.  
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Figure Legends 
 
Figure 1: Dose effect and potential mechanisms for decreasing incidence of coronary heart 
disease by regular ethanol consumption 
 TNF-R1, R2=tumor necrosis factor-receptor 1, 2 
 
Figure2. Hypothetical scheme for cardioprotection by ethanol against myocardial ischemia-
reperfusion injury 
PLC=phospholipase C; PLD=phospholipase D; PKC=protein kinase C; 
PI3K=phosphoinositide 3-kinase; Akt=protein kinase B; GSK3β= glycogen synthase kinase 
3β; pGSK3β=phospho glycogen synthase kinase 3β; PTK=protein tyrosine kinase; ROS= 
reactive oxygen species; JNK= c-Jun N-terminal kinase; ERK= extracellular signal- 
regulated kinase; MAPK= mitogen-activated protein kinase; ALDH2= aldehyde 
dehydrogenase 2; 4-HNE=4-hydroxy-2-nonenal; Bcl2=B-cell leukemia 2 family protein; 
Bad=Bcl2-antagonist of cell death; mPTP=mitochondrial permeability transition pore; 
NO=nitric oxide; eNOS=endothelial nitric oxide synthase． 
Dotted line; to be elucidated. 
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Table 1; Isolated guinea pig hearts were subjected to 45 min of global ischemia and 48 min 
of reperfusion. Experiments were performed in hearts from guinea pigs consuming varying 
concentrations of ethanol in their drinking water for 3, 6, or 12 weeks. A group of hearts 
from animals not exposed to ethanol was subjected to ischemic preconditioning (PC). PC 
was elicited by 2 min of global ischemia and 5 min of reperfusion immediately before 45 min 
of ischemia. Creatine kinase release was measured in the coronary effluent during first 18 
min of reperfusion (3-min intervals). Data are presented as mean ± SEM.  
 
Table 2; Effect of acute and chronic ethanol exposure to hearts against ischemia-
reperfusion injury  
 
 
 
 
